GAMMA Investing LLC Purchases 497 Shares of Artivion, Inc. (NYSE:AORT)

GAMMA Investing LLC boosted its position in shares of Artivion, Inc. (NYSE:AORT) by 21.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,772 shares of the company’s stock after buying an additional 497 shares during the period. GAMMA Investing LLC’s holdings in Artivion were worth $79,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in AORT. JPMorgan Chase & Co. increased its stake in Artivion by 394.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock worth $2,606,000 after acquiring an additional 78,120 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in Artivion in the third quarter worth $5,798,000. Franklin Resources Inc. raised its stake in Artivion by 14.4% during the third quarter. Franklin Resources Inc. now owns 21,107 shares of the company’s stock valued at $553,000 after purchasing an additional 2,663 shares in the last quarter. Tidal Investments LLC lifted its position in Artivion by 602.2% during the third quarter. Tidal Investments LLC now owns 157,002 shares of the company’s stock valued at $4,179,000 after purchasing an additional 134,642 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Artivion by 346.3% in the 3rd quarter. Barclays PLC now owns 70,877 shares of the company’s stock worth $1,888,000 after buying an additional 54,996 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Price Performance

Artivion stock opened at $29.96 on Friday. The firm has a market capitalization of $1.26 billion, a PE ratio of -1,498.00 and a beta of 1.74. Artivion, Inc. has a 12-month low of $16.48 and a 12-month high of $30.45. The firm has a 50-day moving average price of $28.64 and a 200-day moving average price of $26.97. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Oppenheimer upped their target price on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research report on Tuesday, December 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Artivion in a research note on Monday, December 9th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $31.80.

Insiders Place Their Bets

In other Artivion news, CAO Amy Horton sold 4,329 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $29.66, for a total value of $128,398.14. Following the sale, the chief accounting officer now owns 135,660 shares in the company, valued at $4,023,675.60. This trade represents a 3.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Andrew M. Green sold 7,618 shares of Artivion stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the sale, the vice president now owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. This trade represents a 18.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 20,017 shares of company stock valued at $600,007 over the last 90 days. Insiders own 8.10% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.